Aulos Bioscience

Executive Summary

Aulos Bioscience is a clinical-stage immuno-oncology company founded in 2021 and headquartered in Cambridge, Massachusetts. The company is focused on developing best-in-class IL-2 therapeutics to revolutionize cancer care. Its lead candidate, imneskibart (AU-007), is a computationally designed monoclonal antibody that selectively activates anti-tumor immunity while minimizing the immunosuppressive and toxic effects typically associated with IL-2 therapy. AU-007 is currently in Phase 2 clinical trials for solid tumors, building on promising preclinical and Phase 1 data that demonstrated favorable safety and early efficacy signals. By precisely targeting the IL-2 pathway, Aulos aims to unlock the full potential of IL-2 for cancer immunotherapy, addressing a key challenge in the field.

Upcoming Catalysts (preview)

• H2 2026Phase 2 interim data readout for imneskibart (AU-007) in solid tumors35% success
• 2026Potential partnership or licensing deal for AU-007 or platform50% success
• 2027Initiation of Phase 2 combination trial with checkpoint inhibitor40% success